1. Home
  2. RUM vs VERA Comparison

RUM vs VERA Comparison

Compare RUM & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rumble Inc.

RUM

Rumble Inc.

HOLD

Current Price

$7.35

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

Logo Vera Therapeutics Inc.

VERA

Vera Therapeutics Inc.

HOLD

Current Price

$34.53

Market Cap

3.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RUM
VERA
Founded
2013
2016
Country
United States
United States
Employees
135
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
3.2B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RUM
VERA
Price
$7.35
$34.53
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$81.30
AVG Volume (30 Days)
3.1M
957.4K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$209.98
N/A
Revenue Next Year
$40.99
$472.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.62
$18.76
52 Week High
$10.99
$56.05

Technical Indicators

Market Signals
Indicator
RUM
VERA
Relative Strength Index (RSI) 52.74 40.15
Support Level $7.35 $34.04
Resistance Level $8.18 $42.77
Average True Range (ATR) 0.65 2.03
MACD -0.12 -0.12
Stochastic Oscillator 28.88 23.80

Price Performance

Historical Comparison
RUM
VERA

About RUM Rumble Inc.

Rumble Inc is a free-to-use video-sharing platform where users can watch, share, like, comment, and upload their own videos. Users can subscribe to channels to stay in touch with recent creator content and access video-on-demand uploaded, and live content streamed, by creators. Geographically, it generates a majority of its revenue from the United States.

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Share on Social Networks: